TrialAlzheimer's research & therapy2018

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Philip Scheltens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.